HBM HOLDINGS-B(02142) and BaiTu Life Sciences jointly launched MEGASTREAM TECHBIO to create a globally competitive AI research and development ecosystem.

HBM HOLDINGS-B (02142) announced that the company will establish a multi-level, long-term comprehensive strategic partnership with BioMap to collaborate on the development of complex macromolecular drug discovery and development driven by artificial intelligence (AI). The aim is to systematically overcome key research and development bottlenecks for next-generation innovative therapies and jointly create a globally competitive AI research and development ecosystem. According to the strategic cooperation framework, the company and BioMap will jointly establish a new generation AI pipeline research and development company - MegaStream TechBio (MegaStream) for the global market. MegaStream will integrate "exclusive big data exclusive big model large-scale innovative pipeline combination" and build an AI research and development engine centered around an advanced integrated intelligent wet lab and dry lab experimental platform, as well as personalized, multimodal, and multi-attribute generative big models. MegaStream will focus on major unmet clinical needs in areas such as cardiovascular, renal, oncology, and anti-aging, with First-in-Class (FIC) and Best-in-Class (BIC) assets as its core development benchmarks. As the leading initiator, the company will provide MegaStream with access to its globally unique fully human antibody platform, deep target biology expertise, and global clinical development advantages. BioMap will serve as a joint initiator and provide underlying AI technology empowerment, model engineering support, and intelligent research and development capabilities to help the company rapidly advance pipeline research and development processes. The initial pipelines of MegaStream are expected to consist of both past collaborative AI drug development projects between the two parties and newly proposed AI-native pipeline projects. The initiators shall receive potential initial payments, success milestone payments, and equity distribution in accordance with industry practices. Furthermore, the core management team of MegaStream is expected to be composed of senior executives from multinational biopharmaceutical companies and top experts in the field of artificial intelligence, with relevant personnel currently being appointed. BioMap is a global leader in life science AI foundational big models, dedicated to building a new generation of AI infrastructure for the life science industry to improve discovery efficiency. The board of directors believes that the strategic cooperation represents a further deepening of the existing collaboration between the group and BioMap, which is expected to strengthen the group's AI-enabled discovery engine, expand the applications of the group's technology platform, and provide strong support for the group's strategic development of next-generation complex macromolecular drugs.